COSMO Pharmaceuticals SA (0RGI) — Net Asset Quality Index
COSMO Pharmaceuticals SA (0RGI) has a Net Asset Quality Index of 76.5% as of June 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of £610.33 Million minus total liabilities of £143.35 Million yields net assets of £466.98 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check COSMO Pharmaceuticals SA (0RGI) asset resilience to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
COSMO Pharmaceuticals SA Net Asset Quality Index Over Time (2004–2024)
This chart shows how COSMO Pharmaceuticals SA's Net Asset Quality Index has evolved across 21 annual periods from 2004 to 2024. As of June 2025, the index stands at 76.5%, representing net assets of £466.98 Million against total assets of £610.33 Million GBP. See 0RGI current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for COSMO Pharmaceuticals SA (2004–2024)
The table below presents the year-by-year Net Asset Quality Index for COSMO Pharmaceuticals SA from 2004 to 2024, covering 21 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see COSMO Pharmaceuticals SA market cap and net worth.
| Year | Quality Index | Net Assets (GBP) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 78.1% | £505.09 Million | £646.77 Million | £141.68 Million | ▲ +0.6 pp |
| 2023 | 77.4% | £429.04 Million | £553.98 Million | £124.94 Million | ▲ +16.4 pp |
| 2022 | 61.1% | £463.79 Million | £759.59 Million | £295.80 Million | ▼ -2.6 pp |
| 2021 | 63.6% | £512.68 Million | £805.56 Million | £292.88 Million | ▼ -3.5 pp |
| 2020 | 67.1% | £400.12 Million | £596.16 Million | £196.04 Million | ▼ -0.2 pp |
| 2019 | 67.3% | £393.73 Million | £585.16 Million | £191.43 Million | ▼ -3.8 pp |
| 2018 | 71.1% | £444.85 Million | £625.69 Million | £180.83 Million | ▼ -23.3 pp |
| 2017 | 94.4% | £470.12 Million | £497.97 Million | £27.86 Million | ▲ +0.7 pp |
| 2016 | 93.7% | £415.56 Million | £443.47 Million | £27.92 Million | ▲ +1.5 pp |
| 2015 | 92.2% | £403.65 Million | £437.94 Million | £34.30 Million | ▲ +24.7 pp |
| 2014 | 67.5% | £152.29 Million | £225.62 Million | £73.33 Million | ▼ -23.1 pp |
| 2013 | 90.6% | £220.16 Million | £243.00 Million | £22.85 Million | ▲ +8.5 pp |
| 2012 | 82.1% | £124.60 Million | £151.84 Million | £27.24 Million | ▲ +0.8 pp |
| 2011 | 81.3% | £63.43 Million | £78.04 Million | £14.60 Million | ▲ +17.7 pp |
| 2010 | 63.6% | £58.37 Million | £91.83 Million | £33.46 Million | ▼ -20.1 pp |
| 2009 | 83.7% | £59.80 Million | £71.46 Million | £11.67 Million | ▲ +8.8 pp |
| 2008 | 74.8% | £43.24 Million | £57.77 Million | £14.53 Million | ▲ +0.4 pp |
| 2007 | 74.4% | £35.15 Million | £47.23 Million | £12.08 Million | ▲ +51.8 pp |
| 2006 | 22.6% | £5.34 Million | £23.61 Million | £18.27 Million | ▲ +20.4 pp |
| 2005 | 2.2% | £631.00K | £28.21 Million | £27.58 Million | ▲ +6.0 pp |
| 2004 | -3.8% | £-880.00K | £23.46 Million | £24.34 Million | — |